These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 22781570)

  • 1. [Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study].
    Mao Y; Yu JM; Zhan YQ; Hu DY; Ding RJ; Zhang F; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(14):968-73. PubMed ID: 22781570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia].
    Mao Y; Yu JM; Zhang F; Hu DY; Ding RJ; Zhan YQ; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):508-12. PubMed ID: 22943820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia.
    Ose L; Budinski D; Hounslow N; Arneson V
    Atherosclerosis; 2010 May; 210(1):202-8. PubMed ID: 20080236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis].
    Mao Y; Yu JM; Zhan YQ; Hu DY; Ding RJ; Zhang F; Li SC; Kong QY; Lin FL; Jia GX
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1681-5. PubMed ID: 22944158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
    Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
    Davidson MH; Stein EA; Hunninghake DB; Ose L; Dujovne CA; Insull W; Bertolami M; Weiss SR; Kastelein JJ; Scott RS; Campodónico S; Escobar ID; Schrott HG; Bays H; Stepanavage ME; Wu M; Tate AC; Melino MR; Kush D; Mercuri M; Mitchel YB;
    Nutr Metab Cardiovasc Dis; 2000 Oct; 10(5):253-62. PubMed ID: 11213534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-molecular-weight hydroxypropylmethylcellulose. A cholesterol-lowering agent.
    Dressman JB; Adair CH; Barnett JL; Berardi RR; Dunn-Kucharski VA; Jarvenpaa KM; Parr DD; Sowle CA; Swidan SZ; Tobey SW
    Arch Intern Med; 1993 Jun; 153(11):1345-53. PubMed ID: 8507125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
    Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.